Author:
McTiernan Anne M.,Cassoni Anna M.,Driver Deirdre,Michelagnoli Maria P.,Kilby Anne M.,Whelan Jeremy S.
Abstract
The outcome for patients with relapsed Ewing's sarcoma is poor. A retrospective analysis was carried out to identify factors associated with improved survival. Between 1992 and 2002, 114 patients presented with relapsed or progressive disease. Median time to progression/relapse was 13 months (range, 2–128). Treatment at relapse included high dose treatment (HDT) in 29 patients, and surgery or definitive radiotherapy in 29. 2 and 5-year post relapse survival (PRS) was 23.5% and 15.2%, respectively. In multivariate analysis, the most significant factors associated with improved survival were disease confined locally or to the lungs (2-year PRS, 40% versus 6%;P<.001), relapse>18months from diagnosis (2-year PRS, 53% versus 8%;P<.001), HDT at relapse (2-year PRS, 62% versus 11%;P<.001), and surgery and/or radiotherapy at relapse (2-year PRS, 51% versus 14%;P<.001). First treatment failure in Ewing's sarcoma is mostly fatal. Improved survival can be achieved in selective patients with aggressive treatment. These improvements are confined to those without bone or bone marrow metastases.
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献